S&P 500   5,066.64 (+1.70%)
DOW   38,879.69 (+0.69%)
QQQ   436.10 (+2.46%)
AAPL   183.04 (+0.39%)
MSFT   409.79 (+1.89%)
META   486.75 (+4.00%)
GOOGL   143.63 (+0.76%)
AMZN   172.25 (+2.17%)
TSLA   194.10 (-0.34%)
NVDA   776.34 (+15.06%)
NIO   5.77 (-3.35%)
AMD   183.16 (+11.49%)
BABA   75.71 (+0.17%)
T   16.63 (-2.18%)
F   12.17 (+0.25%)
MU   85.66 (+5.12%)
CGC   3.39 (-1.45%)
GE   151.58 (+1.68%)
DIS   108.23 (+0.52%)
AMC   4.41 (-3.50%)
PFE   27.30 (-1.34%)
PYPL   58.27 (+1.37%)
XOM   105.19 (+0.32%)
S&P 500   5,066.64 (+1.70%)
DOW   38,879.69 (+0.69%)
QQQ   436.10 (+2.46%)
AAPL   183.04 (+0.39%)
MSFT   409.79 (+1.89%)
META   486.75 (+4.00%)
GOOGL   143.63 (+0.76%)
AMZN   172.25 (+2.17%)
TSLA   194.10 (-0.34%)
NVDA   776.34 (+15.06%)
NIO   5.77 (-3.35%)
AMD   183.16 (+11.49%)
BABA   75.71 (+0.17%)
T   16.63 (-2.18%)
F   12.17 (+0.25%)
MU   85.66 (+5.12%)
CGC   3.39 (-1.45%)
GE   151.58 (+1.68%)
DIS   108.23 (+0.52%)
AMC   4.41 (-3.50%)
PFE   27.30 (-1.34%)
PYPL   58.27 (+1.37%)
XOM   105.19 (+0.32%)
S&P 500   5,066.64 (+1.70%)
DOW   38,879.69 (+0.69%)
QQQ   436.10 (+2.46%)
AAPL   183.04 (+0.39%)
MSFT   409.79 (+1.89%)
META   486.75 (+4.00%)
GOOGL   143.63 (+0.76%)
AMZN   172.25 (+2.17%)
TSLA   194.10 (-0.34%)
NVDA   776.34 (+15.06%)
NIO   5.77 (-3.35%)
AMD   183.16 (+11.49%)
BABA   75.71 (+0.17%)
T   16.63 (-2.18%)
F   12.17 (+0.25%)
MU   85.66 (+5.12%)
CGC   3.39 (-1.45%)
GE   151.58 (+1.68%)
DIS   108.23 (+0.52%)
AMC   4.41 (-3.50%)
PFE   27.30 (-1.34%)
PYPL   58.27 (+1.37%)
XOM   105.19 (+0.32%)
S&P 500   5,066.64 (+1.70%)
DOW   38,879.69 (+0.69%)
QQQ   436.10 (+2.46%)
AAPL   183.04 (+0.39%)
MSFT   409.79 (+1.89%)
META   486.75 (+4.00%)
GOOGL   143.63 (+0.76%)
AMZN   172.25 (+2.17%)
TSLA   194.10 (-0.34%)
NVDA   776.34 (+15.06%)
NIO   5.77 (-3.35%)
AMD   183.16 (+11.49%)
BABA   75.71 (+0.17%)
T   16.63 (-2.18%)
F   12.17 (+0.25%)
MU   85.66 (+5.12%)
CGC   3.39 (-1.45%)
GE   151.58 (+1.68%)
DIS   108.23 (+0.52%)
AMC   4.41 (-3.50%)
PFE   27.30 (-1.34%)
PYPL   58.27 (+1.37%)
XOM   105.19 (+0.32%)
NASDAQ:AVNR

(AVNR) (AVNR) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AVNR stock logo

About (AVNR) Stock (NASDAQ:AVNR)

AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).


AVNR Stock News Headlines

5 Stocks Facing an Earnings Short Squeeze
Stock To Watch In 2024
Don't wait. Discover this company's major updates happening now.
5 Biotech Options to Buy Right Now
Stock To Watch In 2024
Don't wait. Discover this company's major updates happening now.
Davenport PD warns of utility worker scam
8 Stocks Under $10 Moving Higher
See More Headlines
Receive AVNR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (AVNR) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:AVNR
CUSIP
05348P40
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report














AVNR Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of (AVNR) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (AVNR) investors own include Avid Bioservices (CDMO), (GTATQ) (GTATQ), Netflix (NFLX), Nokia Oyj (NOK), Alterity Therapeutics (PRAN), Ariad Pharmaceuticals (Aria), Alphabet (GOOG), Groupon (GRPN) and Intel (INTC).

This page (NASDAQ:AVNR) was last updated on 2/22/2024 by MarketBeat.com Staff